Ad
BGNE Short Information BeiGene Ltd.
home / stock / bgne / bgne short
Short Information | BeiGene Ltd. (NASDAQ:BGNE)
| Twenty Trading Day Totals | |
|---|---|
| Total Shorted Volume | 1,287,369 |
| Total Actual Volume | 7,745,646 |
| Short Trends | |
|---|---|
| Cover Days | 19 |
| Short Days | 0 |
| No Change Days | 1 |
| Averages | |
|---|---|
| Average Short Volume | 64,368 |
| Average Short Percentage | 17.18% |
Is there a BGNE Short Squeeze or Breakout about to happen?
See the BGNE Short Analysis for free Sign up or Login
Powered by Squeeze Report
BGNE Twenty Trading Day's Volume to Short Volume Chart
BGNE Twenty Trading Day Price Chart
BGNE Short Data Results Days
| Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
|---|---|---|---|---|---|---|---|
| 12-31-2024 | $184 | $184.71 | $187.42 | $183.91 | 331,631 | 65,015 | 19.6% |
| 12-30-2024 | $180.08 | $183.81 | $185.24 | $179.73 | 178,913 | 52,708 | 29.46% |
| 12-27-2024 | $181.81 | $181.89 | $184.91 | $180.26 | 169,767 | 35,165 | 20.71% |
| 12-26-2024 | $181.58 | $184.68 | $184.98 | $180.99 | 163,887 | 28,413 | 17.34% |
| 12-24-2024 | $177.72 | $181.62 | $182.33 | $177.085 | 148,370 | 52,189 | 35.17% |
| 12-23-2024 | $178.63 | $177.7 | $179.93 | $176.57 | 231,186 | 38,705 | 16.74% |
| 12-20-2024 | $176.29 | $176.5 | $179.25 | $175.8 | 368,466 | 42,934 | 11.65% |
| 12-19-2024 | $175.18 | $174.72 | $177.3 | $170.99 | 296,091 | 52,968 | 17.89% |
| 12-18-2024 | $177.56 | $175.87 | $178.69 | $174.511 | 592,487 | 101,314 | 17.1% |
| 12-17-2024 | $178 | $179.06 | $179.585 | $176.055 | 366,173 | 37,463 | 10.23% |
| 12-16-2024 | $177.69 | $176.33 | $180 | $174.5 | 538,230 | 90,204 | 16.76% |
| 12-13-2024 | $177.15 | $179.35 | $179.65 | $176.15 | 368,615 | 46,210 | 12.54% |
| 12-12-2024 | $184.02 | $180.27 | $186.35 | $179.69 | 387,828 | 41,999 | 10.83% |
| 12-11-2024 | $186.92 | $184.38 | $187.64 | $183.26 | 491,546 | 59,089 | 12.02% |
| 12-10-2024 | $195.52 | $187.5 | $196.96 | $183.2924 | 1,260,783 | 266,255 | 21.12% |
| 12-09-2024 | $209.1 | $207.62 | $211 | $203.585 | 513,042 | 79,073 | 15.41% |
| 12-06-2024 | $207.72 | $205.62 | $209.46 | $204.085 | 348,989 | 46,387 | 13.29% |
| 12-05-2024 | $204.47 | $201.66 | $204.99 | $200.005 | 254,671 | 40,612 | 15.95% |
| 12-04-2024 | $203.37 | $199.09 | $206.425 | $198.7 | 339,750 | 40,899 | 12.04% |
| 12-03-2024 | $206.22 | $206.01 | $208.23 | $202.635 | 395,221 | 69,767 | 17.65% |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
New indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers Second FDA approval for TEVIMBRA in 2024 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 68823...
-
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to “ONC” on January 2, 2025, reflecting its long-standing commitment to delivering innovati...
-
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (“CSPC”)...